Loading patent…
AssigneesGlaxosmithkline Biologicals SA, Corixa Corporation
InventorsBrenda Barth, Ajay Bhatia, Mark Alderson, Jean-Francois L. Maisonneuve, Yves Lobet, Florence Bernadette Nozay, Martine Marchand, Pascal Mettens, Yasir A. Skeiky, Peter Probst
Estimating the term…
The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.
A composition comprising a combination of two or more Chlamydia proteins or immunogenic fragments thereof or a polynucleotide or polynucleotides encoding them, said two or more proteins or immunogenic fragments selected from Swib, Momp, Ct-858, Ct-875, Ct-622, Ct-089, passenger domain of PmpG (PmpGpd) and passenger domain of PmpD (PmpDpd).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composition comprising one of the following combinations of Chlamydia polypeptides or immunogenic fragments thereof or polynucleotides encoding them:
(canceled)
A composition comprising one of the following combinations of Chlamydia polypeptides or immunogenic fragments thereof or polynucleotides encoding them
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for the treatment or prevention of Chlamydial infection by a second Chlamydia trachomatis serovar, comprising the administration of a vaccine comprising one or more Chlamydial proteins, immunogenic fragments thereof or polynucleotides encoding them, selected from the list consisting of Ct-089, Ct-858 and Ct-875, and which are derived from a first Chlamydia trachomatis serovar.
(canceled)
(canceled)
(canceled)
(canceled)
37-44. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for determining prior Chlamydial infection in an individual comprising:
57-68. (canceled)
Dependencies are inferred from the claim text.